T-cell Immunity Optimized Cure (TIOC) Therapeutics

TIOC Therapeutics is a South Korean biotechnology company dedicated to developing next-generation T-cell therapies for the treatment of solid tumors. The company utilizes its proprietary T-cell Immunity Optimized Cure (TIOC) platform to enhance the persistence and anti-tumor activity of T-cells within the immunosuppressive tumor microenvironment. Their pipeline includes innovative CAR-T and TCR-T candidates designed to overcome the limitations of current immunotherapies in treating complex cancers. TIOC aims to provide curative options for patients with refractory or metastatic solid malignancies through advanced cellular engineering. The company was founded by academic experts in immunology and is supported by prominent Korean venture capital firms.